NEWS

Sensus Healthcare unveils streamlined design for signature skin cancer treatment system at world’s largest radiation oncology conference – ASTRO

Events / Press Release



November 2, 2010

San Diego, CA

A new technology company committed to providing a viable treatment option for millions of skin cancer sufferers unveiled a re-design of its signature system this week at the American Society for Radiation Oncology (ASTRO) Annual Conference. ASTRO is the largest radiation oncology society in the world, with more than 10,000 members.

Sensus Healthcare is now showing the newly redesigned SRT-100™, which offers improved mobility features and a streamlined look. The SRT-100™ is powered with a standard electrical outlet.

The SRT-100™ design revisions do not affect the core system, which is cleared by the FDA, UL and has ISO/CE Mark certification. The Sensus Healthcare SRT-100™ is the only system of its kind available in the U.S. to treat non-melanoma skin cancers, and is now in use worldwide.

The SRT-100™ treats basal cell and squamous cell skin cancers, especially those requiring difficult or extensive surgery with sensitive areas in the head and neck regions – the fold in the nose, eyelids, lips, corner of the mouth, and the lining of the ear – that would otherwise lead to a less than desirable cosmetic outcome. The SRT-100™ treatment procedure does not require the use of anesthetics or skin grafting.

“The Sensus Healthcare treatment option is in no way intended to replace Mohs surgery, which is the standard surgical treatment option for skin cancer patients and an absolute necessity in many cases,” Sensus Chief Executive Officer Joe Sardano said. “However, when surgery is not essential, Sensus offers a viable alternative, one that uses safe and effective low-energy radiotherapy to treat non-melanoma skin cancers. It is a non-invasive process for millions of skin cancer sufferers worldwide.”

“Many skin cancer patients may not even know that they have treatment options beyond surgery, which can lead to scarring and infection,” Sensus Healthcare Chief Operating Officer Kal Fishman added. “Part of the process is educating the public that there are other ways to treat certain types of skin cancer – particularly around the face and neck, where four in five skin cancer cases develop.”

 Sensus Healthcare will also exhibit the SRT-100™ at the 2011 American Academy of Dermatology Annual Meeting in New Orleans on February 4-8.

 

About SENSUS Healthcare – Taking new aim at skin cancer, Sensus Healthcare is focused on the design, manufacture and marketing of products and services that incorporate proprietary mobile X-ray technology for cost-effective, non-invasive treatment of non-melanoma skin cancers. The signature Sensus Healthcare product, the SRT-100™, meets stringent safety requirements set by the FDA, UL and ISO/CE Mark certification. Based in Boca Raton, Fla., Sensus employs best-practice standard operational procedures to ensure quality control, high-grade customer support, optimized success in field operations, and product reliability. For more information, visit www.sensushealthcare.com.

 
Sensus Healthcare Inquiries:
Chris Lato
Chris.lato@avicomdirect.com
Office: 262.953.4272
Cell: 608.219.7231

The Benefits of SRT

Along with eliminating the risks for post-surgical infections and complications, the SRT-100™ provides patients and physicians with a safe and effective treatment option that offers many benefits, including:

  1. 95%+ cure rates that rival surgery
  2. No anesthesia, cutting, bleeding, stitching or pain
  3. No downtime or lifestyle restrictions
  4. Super cosmesis, no unsightly scarring
  5. No need for post-treatment reconstructive surgeries